# Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

> **NCT00515086** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Everolimus
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT00515086
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Early termination due to slow enrollment and protocol-defined stopping rule.
- **Last updated:** 2011-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515086, "Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00515086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*